SINGAPORE
Law
Welcome Guest | ログイン
検索
詳細検索
Oxford Handbook of Practical Drug Therapy (Oxford Handbooks Series) (2ND): Richards, Duncan/ Coleman, Jamie/ Reynolds, John/ Aronson, Jeffrey: BOOKS KINOKUNIYA
詳細
Oxford Handbook of Practical Drug Therapy (Oxford Handbooks Series) (2ND)
Oxford Handbook of Practical Drug Therapy (Oxford Handbooks Series) (2ND)
出版社 : Oxford Univ Pr
出版年月 : 2012/01
Binding : Paperback
ISBN : 9780199562855

BookWeb価格 : S$ 59.94
会員価格 : S$ 53.95

在庫情報 : 配送センターに在庫があります。
通常、5日以内に発送いたします。
言語 : English
Stock Information
Store Shelf Location Click here Stock
Singapore Main Store G11-02, G12-06, G11-05 Map
Liang Court Store -
Bugis Junction Store -
Important
  • While every attempt has been made to ensure stock availability, occasionally we do run out of stock at our stores.
  • Retail store and online prices may vary.
  • To confirm availability and pricing, please call the store directly.
Retail Store Contact Details and Operating Hours

内容情報
Source: ENG
Place of Publication: Great Britain
Edition: Subsequent
Academic Level: Professional
Table of Contents
 
Symbols and abbreviations                          xv
How to use this book                               xxi
Introductory sections                              1  (30)
  Prescribing
    The drug history                               2  (3)
    Writing a prescription                         5  (1)
    Generic drugs and biosimilars                  6  (1)
    Repeat prescriptions                           7  (2)
    Off-licence drugs Cautionary and advisory      9  (1)
    labels
  Some basic concepts
    The World Health Organization (WHO)            10 (1)
    essential medicines list
    Compliance, adherence, and concordance         11 (1)
    Guidelines                                     12 (2)
    Dose-response curves (concentration-effect     14 (1)
    curves)
    Efficacy of drugs                              15 (1)
    Adverse drug reactions                         16 (2)
    Drug-drug interactions                         18 (2)
    Placebos                                       20 (1)
    Changing the doses of drugs                    21 (1)
    Renal insufficiency                            22 (1)
    Hepatic insufficiency                          22 (1)
    An approach to rational prescribing            23 (1)
    Paediatric prescribing                         24 (2)
    Drugs and pregnancy                            26 (2)
    Drug therapy and breastfeeding                 28 (2)
    Drug development                               30 (1)
1 Gastrointestinal system                          31 (50)
  Gastric acid suppression
    Histamine H., receptor antagonists BNF 1.3.1   32 (2)
    Proton pump inhibitors (PPIs) BNF 1.3.5        34 (4)
    Misoprostol BNF 1.3.4, 10.1.1                  38 (4)
  Drugs affecting gastrointestinal motility
    Constipation BNF 1.6                           42 (2)
    Co-phenotrope (Lomotilョ) BNF 1.4.2             44 (2)
    Loperamide (Imodiumョ) BNF 1.4.2                46 (2)
  Inflammatory Bowel Disease
    Mesalazine and related compounds               48 (4)
    (aminosalicylates) BNF 1.5
    Su ifasalazine BNF 1.5.1 and 10.13             52 (2)
  Liver, biliary system, and lipids
    Cholic acids BNF 1.9.1                         54 (2)
    HMG CoA reductase inhibitors ('statins')       56 (4)
    BNF 2.12
    Ezetirnibe BNF 2.12                            60 (2)
    Fibrates BNF 2.12                              62 (2)
  Obesity
    Orlistat BNF 4.5.1                             64 (2)
  Antiemetics
    Metoclopramide BNF 4.6                         66 (4)
    Prochlorperazine (Stemetir) BNF 4.6            70 (6)
    Domperidone BNF 4.6                            76 (2)
    Serotonin 5-HT3 receptor antagonists BNF 4.6   78 (3)
2 Cardiovascular system                            81 (160)
  A pharmacological approach to the treatment      84 (2)
  of arrhythrnias BNF 2.3.1
  Antiarrhythmic drugs
    Adenosine BNF 2.3.2                            86 (4)
    Flecainide BNF 2.3.2                           90 (4)
    Cardiac glycosides (digitalis) BNF 2.1.1,      94 (6)
    2.3.1. and 2.5.5
    Disopyramide BNF 2.3.2                         100(4)
    Amiodarone BNF 2,3.2 and 2.7.3                 104(6)
  Anticoagulants, antiplatelet drugs, and
  fibrinolytic drugs
    Heparins (unfractionated and low molecular     110(8)
    weight) BNF 2.8.1
    Direct thrombin inhibitors BNF 2.8.2           118(2)
    Fondaparinux sodium BNF 2.8.1                  120(4)
    Warfarin BNF 2.8.2                             124(8)
    Acetylsalicylic acid (aspirin) BNF 2.9 and     132(6)
    4.7.1
    Clopidogrel BNF 2.9                            138(4)
    Dipyridamole BNF 2.9                           142(2)
    Glycoprotein Ilbillia antagonists BNF 2.9      144(2)
    Fibrinolytic drugs BNF 2.10.2 and 13.11.7      146(4)
  Ischaemic Heart Disease
    Pharmacology of drugs used to treat acute      150(1)
    coronary syndromes, including myocardial
    infarction BNF 2.10
    Pharmacology of drugs used to treat heart      151(1)
    failure
    Nitrate drugs BNF 2.6.1                        152(4)
    Nicorandil BNF 2.6.3                           156(2)
    Beta-adrenoceptor antagonists                  158(8)
    ('beta-blockers') BNF 2.4, 2.5.5, 6.2.2,
    4.7.4, 11.6
    Angiotensin converting enzyme inhibitors       166(6)
    (ACE inhibitors) BNF 2.5.5.1
    Angiotensin receptor antagonistsiblockers      172(4)
    (ARBs) BNF 2.5.5.2
  Hypertension
    An approach to the treatment of                176(2)
    hypertension BNF 2.5
    Methyldopa (alpha-methyldopa) BNF 2.5.2        178(2)
  Calcium channel blockers
    Calcium channel blockers (see also             180(2)
    individual sections) BNF 2.6.2
    Dihydropyridines (nifedipine-like) BNF 2.6.2   182(4)
    Benzothiazepines (diltiazem) BNF 2.6.2 and     186(2)
    2.3.2
    Phenylalkylamines (verapamil) BNF 2.6.2 and    188(2)
    2.3.2
  Intravenous Fluids
    Crystalloid solutions for intravenous          190(4)
    infusion BNF 9.7
    Colloid solutions for intravenous infusion     194(3)
    BNF 9.2
  Diuretics
    Sites of action of diuretics BNF 2.2           197(1)
    Treatment of pulmonary oedema BNF 2.2          198(2)
    Loop diuretics BNF 2.2.2 and 2.2.4             200(6)
    Thiazide and thiazide-like diuretics BNF       206(4)
    2.7.1, 2.5.5, and 6.5.2
    Potassium-sparing diuretics (amiloride and     210(4)
    triamterene) BNF 2,2.3 and 2.2.4
    Spironolactone and eplerenone BNF 2.2.3,       214(4)
    2.2.4, and 2.5.5
  Adrenoceptor agonists
    Adrenoceptor agonists (sympathomimetics)       218(8)
    BNF 2.7
  Antimuscarinic drugs
    Muscarinic acetylcholine receptor              226(6)
    antagonists (atropine and related
    compounds) BNF 35.1.3, 4.6, 4.9.2, 7.4.2,
    and 11.5
  Endothelin receptor antagonists
    Endothelin receptor antagonists BNF 2.5.1      232(4)
  Drugs for erectile dysfunction
    Phosphodiesterase type V inhibitors BNF        236(5)
    7.4.5
3 Respiratory system                               241(38)
  Oxygen
    Oxygen BNF 3.6                                 242(4)
  Asthma and chronic obstructive pulmonary
  disease (COPD)
    Pharmacology of drugs used to treat asthma     246(2)
    BNF 3.1
    An approach to the treatment of chronic        248(2)
    obstructive pulmonary disease (COPD) BNF 3.2
    Short-acting 132 adrenoceptor agonists BNF     250(4)
    3.1.1.1 and 7.1.3
    Long-acting 132 adrenoceptor agonists BNF      254(4)
    3.1.1.1
    Bronchodilatory muscarinic receptor            258(4)
    antagonists BNF 3.1.2
    Leukotriene receptor antagonists BNF 3.3.2     262(2)
    Cromones BNF 3.3.1.1.5, and 11.4.2             264(2)
    Xanthine derivatives BNF,3.1.3                 266(6)
  Respiratory stimulants
    Doxaprarn BNF 3.5.1                            272(2)
  Smoking cessation
    Nicotine BNF 4.10                              274(2)
    Bupropion (amfebutamone) BNF 4.10              276(3)
4 Central nervous system                           279(94)
  Anticonvu Isants
    Carbamazepine BNF 4.8.1, 4.7.3, 6.5.2, 6.1.5   280(8)
    Phenytoin BNF 4.8.1, 4.8.2 and 4.7.3           288(6)
    Sodium valproate BNF 4.8.1                     294(4)
    Lamotrigine BNF 4.8.1                          298(4)
    Other antiepileptic drugs BNF 4.8.1            302(2)
    Barbiturates BNF 4.1.3. 4.8.1 and 15.1.1       304(4)
  Anxiolytics and hypnotics
    Benzediazepines BNF 4.1.1, 4.1.2 and 4.8.2     308(8)
    Renzodiazepine-like hypnotics BNF 4.1.1        316(2)
  Depression
    Tricyclic antidepressants BNF 4.3.1, 6.1.5,    318(6)
    4.7.4.2 and 7.4.2
    Selective serotonin reuptake inhibitors        324(6)
    (SSRIs) BNF 4.3.3
    Venlafaxine BNF 4.3.4                          330(2)
    Monoamine oxidase inhibitors (MAOIs) ar4F      332(4)
    4.3.2, 4.9.1
  Psychoses and bipolar disorder
    Antipsychatic/neuroleptic drugs BNF 4,2        336(6)
    Atypical antipsychotic drugs BNF 4.2.1         342(6)
    Lithium BNF 4.2.3                              348(4)
  Parkinson's disease
    Pharmacology of drugs used to treat            352(2)
    Parkinson's disease BNF 4.9
    Levodopa (L-dopa) BNF 4.9.1                    354(4)
    Dopamine receptor agonists BNF 4.9.1 and       358(4)
    6.7.1
    Entacapone BNF 4.9.1 and 6.7.1                 362(2)
  Anticholinesterases
    Acetylcholinesterase inhibitors BNF 10.2.1,    364(4)
    4.11, 15.1.6, 7.4,1 and 1.6.2
  Migraine
    Serotonin 5-HT1 receptor agonists              368(5)
    ('triptans') BNF 4.7.4
5 Infections                                       373(78)
  Antibacterial drugs
    Penicillins BNF 5.1.1                          374(4)
    Carbapenems BNF 5.1.2                          378(2)
    Cephalosporins and cephamycins BNF 5.1.2       380(4)
    Glycopeptide antibiotics BNF 5.1.7             384(4)
    Tetracyclines BNF 5.1.3 and 13.6.2             388(6)
    Aminoglycoside antibiotics BNF 5.1.4           394(4)
    Macrolide antibiotics BNF 5.1.5                398(6)
    Sulfonamides and trimethoprim (including       404(6)
    co-trimoxazole) BNF 5.12 and 13.10.1.1
    Metronidazole and tinidazole BNF 5.1.11        410(4)
    Quinolone antibiotics BNF 5.1.12               414(4)
  Antituberculosis drugs
    Antituberculosis drugs BNF 5.1.9               418(4)
  Antiviral drugs
    Antiviral guanine derivatives BNF 5.3,         422(6)
    11.3.3, and 13.10.3
    Drugs used to treat human immunodeficiency     428(8)
    virus (HIV) infection BNF 5.3
  Antifungal drugs
    Imidazole and triazole antifungal drugs BNF    436(4)
    5.2, 7.2.2, 12.3.2, and 13.10.2
    Polyene antifungal drugs BNF 5.2, 7.2.2,       440(4)
    12.3.2, and 13.10.2
  Antimalarial drugs
    Antimalarial drugs BNF 5.4.1                   444(7)
6 Endocrine system; obstetrics and gynaecology     451(84)
  Diabetes mellitus
    Insulin BNF 6.1.1                              452(10)
    Glucagon BNF 6.1.4                             462(2)
    Sulfonylureas BNF 6.1.2,1                      464(4)
    Meglitinides BNF 6.1.2.3                       468(2)
    Biguanides (metformin) BNF 6.1.2.2             470(4)
    Thiazolidinediones ('glitazones') BNF          474(4)
    6.1,2,3
  Thyroid disease
    Thyroid hormones BNF 6.2.1                     478(4)
    Carbirnazole BNF 6.2.2                         482(4)
  Corticosteroids
    Corticosteroids BNF 6.3                        486(2)
    Glucocorticoids BNF 6.3                        488(8)
  Corticotrophins
    Corticotrophins BNF 6.5.1                      496(2)
  Sex steroids
    Oestrogens and hormone replacement therapy     498(4)
    (HRT) BNF 6.4.1, 7.2.1 and 8.3.1
    Progestogens BNF 6.4.1.2, 8.3.2, and 7.3       502(2)
    Oral contraceptives BNF 7.3                    504(4)
    Notes on contraceptive devices BNF 7.3.2.3,    508(2)
    7.3.3, and 7.14
    Gonadorelln analogues BNF 6.7.2 and 8.3.4.1    510(2)
    & 2
    Androgens and anabolic steroids BNF 6.4,2      512(4)
    and 6.4.3
    Antiandrogens BNF 8.3.4.2, 6.4,2 and 13.6.2    516(4)
    Selective oestrogen receptor modulators        520(4)
    (SERMs) BNF 8.3.4.1 and 6.5.1
    Aromatase inhibitors BNF 8.3.4.1               524(2)
  Obstetrics
    Prostaglandins BNF 7.1.1,7.4.5, and 11.6       526(4)
    Oxytocin BNF 7.1.1                             530(2)
  Somatostatin and analogues
    Somatostatin and analogues BNF 8.3.4.3         532(3)
7 Kidneys and the urinary tract                    535(18)
  Drugs and the kidneys
    Renal insufficiency BNF 7.4.3                  536(2)
    Drug-induced renal damage BNF 7.4,3            538(2)
    Drugs and renal stones BNF 7.43                540(2)
    Drugs and renal replacement therapy            542(2)
    (dialysis or filtration) BNF 7.4,3
    Drugs used in the management of chronic        544(2)
    renal insufficiency BNF 7.4.3
  Urinary tract
    Alpha-adrenoceptor antagonists                 546(4)
    (alpha-blockers) BNF 7.4.1 and 2.5.4
    Antidiuretic hormone (ADH, vasopressin) and    550(3)
    analogues SNF 7.4.1 and 7.4.2
8 Malignant disease and immunosuppression          553(44)
  Drugs used to treat cancer
    Drugs used to treat cancer BNF 8.1             554(2)
    Adverse effects of cytotoxic chemotherapy      556(2)
    BNF 8.1
    Chlorambucil BNF 8.1.1                         558(2)
    Cyclophosphamide BNF 8.1.1                     560(2)
    Cytotoxic antibiotics BNF 8.1.2                562(4)
    Antimetabolite drugs BNF 8.1.3, 10.1.3, and    566(4)
    13.5.2
    Methotrexate BNF 8:1.3, 10.1.3, and 13.5.2     570(4)
    Vinca alkaloids BNF 8.1.4                      574(2)
    Platinum compounds BNF 8.1.5                   576(2)
    Taxanes BNF 8.1.5                              578(2)
    Cytotoxic monoclonal antibodies BNF 8.1.5      580(4)
    and 8.2.3
  Immunosuppression
    Azathioprine and mercaptopurine BNF 8.2,       584(4)
    8.1.3, 1.5. 10.1.3, and 10.2.1
    Mycophenolate mofetit and mycophenolic acid    588(4)
    BNF 8.2.1
    Ciclosporin, tacrolimus, and sirolimus BNF     592(5)
    8.2.2 and 13.5.3
9 Nutrition and blood                              597(42)
  Blood, blood products, and anaemia
    Drugs and anaemia BNF 9.1                      598(2)
    Blood transfusion                              600(4)
    Factor VIII and related products BNF 2.11      604(4)
    Erythropoietin and analogues BNF 9.1.3         608(4)
    Colony stimulating factors BNF 9.1.6           612(2)
    Iron salts BNF 9.1.1                           614(4)
    Folic acid and folinic acid BNF 9.1.2 and      618(2)
    8.1
    Vitamin Bit taNF 9.1.2                         620(2)
    Desferrioxamine (deferoxamine) BNF 9.1.3       622(2)
  Minerals
    Calcium salts ONE 9.5.1.1 and 9.6.4            624(2)
    Magnesium sulphate BNF 9.5.1.3                 626(2)
    Potassium chloride BNF 9.2.1.1                 628(4)
  Vitamins
    Vitamin D analogues ONE 9.6.4 and 13.5.2       632(4)
    Vitamin K1 ONE 9.6.6                           636(3)
10 Musculoskeletal and joints                      639(38)
  Gout
    Coichicine ONE 10.1.4                          640(2)
    Allopurinol ONE 10.1.4 and 8.1                 642(2)
  Rheumatoid arthritis (disease-modifying drugs)
    Rheumatoid arthritis (disease-modifying        644(2)
    drugs) BNF 10.1
    Chloroquine and hydroxychloroquine BNF         646(4)
    5.4.1 and 10.1.3
    Gold salts BNF 10.1.3                          650(2)
    Leflunomide BNF 10.1.3                         652(2)
    Tumour necrosis factor (TNF) blocking drugs    654(4)
    BNF 10.1.3 and 1.5.3
  Osteoporosis
    Calcitonin BNF 6.6.1 and 9.5.1.2               658(2)
    Bisphosphonates BNF 6.6.2 and 9.5.1.2          660(6)
  Drugs affecting muscle
    Baciofen BNF 10.2.2                            666(2)
    Dantrolene BNF 15.1.8 and 10.2.2               668(2)
    Neuromuscular blocking drugs BNF 15.1.5        670(4)
    Botulinum toxin BNF 4.9.3                      674(3)
11 Eye                                             677(10)
  Glaucoma
    Acetylcholine receptor agonists BNF 11.6,      678(2)
    12.3.5, and 7.4.1
    Carbonic anhydrase inhibitors BNF 11.6,        680(4)
    4.8, and 2.2.7
    Drugs for macular degeneration BNF 11.8.2      684(3)
12 Skin                                            687(8)
  Antihistamines
    Antihistamines BNF 3.4.1, 13.5.1, 11.4.2,      688(4)
    4.6, and 12.2.1
  Retinoids
    Retinoids BNF 13.6.1, 8.15, 13.5.2 and         692(3)
    13.8.1
13 Poisoning                                       695(24)
  Treatment of poisoning
    An approach to the poisoned patient            696(2)
    Activated charcoal                             698(2)
  Antidotes
    Acetylcysteine (Parvolex)                      700(4)
    Opioid antagonists BNF 15.1.7                  704(6)
    Flumazenil BNF 15.1.7                          710(2)
    Penicillamine BNF 9.8.1 and 10.1.3             712(4)
  Diagnostic agents
    Diagnostic agents                              716(3)
14 Immunological products and vaccines             719(16)
  Immunoglobutins
    Immunoglobulins BNF 14.5 and 14.2              720(4)
  Interferons
    Interferons BNF 8.2.4, 5.3, and 14.5           724(4)
  Vaccines
    Vaccines BNF 14.1                              728(4)
    UK immunization schedule BNF 14.1 and 14.4     732(3)
15 Relief of pain and anaesthetic drugs            735(44)
  Analgesics
    Palliative care                                736(2)
    Paracetamol (acetaminophen) BNF 4.7.1          738(4)
    Non-steroidal anti-inflammatory drugs          742(6)
    (NSAIDS) BNF 10.1.1 and 15.1.4.2
    Codeine phosphate and dihydrocodeine BNF       748(4)
    4.7.1, 4.7.2, 1.4.2 and 3.9.1
    Opiates and non-opiate narcotic analgesics     752(8)
    BNF 4.7.2 and 15,1.4.3
    Treatment of neuropathic pain BNF 4.7.3.       760(2)
    Pregabalin BNF 4.7.3 and 4.8.1                 762(2)
    Gabapentin BNF 4.7.3, 4.8.1 and 6.1.5          764(2)
    Capsaicin BNF 10.3.2, 4.7.3, and 6.1.5         766(2)
    Lidocaine (lignocaine) BNF 2.3.2 and 15.2      768(4)
    Prepofol BNF 15.4.1                            772(4)
    Volatile anaesthetics BNF 15.1.2               776(3)
Drug index                                         779(10)
Subject index                                      789
 

Safe and effective prescribing is a cornerstone of proper patient care. There has in recent years been a significant increase in the numbers of healthcare professionals able to prescribe; however, sources of drug information tend to focus on only one area of prescribing. The Oxford Handbook of Practical Drug Therapy links practical information about how to use medicines with concise details about the pharmacology of a drug, and the principles of clinical pharmacology that govern its action. The overall structure of this handbook is similar to the UK national formulary, with topics on each drug arranged broadly by therapeutic category. When a drug has several different uses, these are brought together in a single topic, allowing the reader to appreciate its full range of actions, whether therapeutic or adverse.Each drugs topic provides information in a clearly laid out and standardised form, and includes a graphical representation of the pharmacological actions of the drug, and its potential uses, practical advice on a drug's major indications, a list of common and serious adverse effects, major drug-drug interactions, practical advice on monitoring for therapeutic and adverse effects, and what to tell the patient. Teaching points throughout the text draw out pharmacological principles, so that readers can increase their basic knowledge by linking theory with practical examples. Also included are several boxes giving guidance on the approach to therapy of specific diseases an clinical problems. In some cases, algorithms for the treatment of medical emergencies are given, and this new edition features case histories throughout the text to illustrate the issues one may face in practical prescribing. The Oxford Handbook of Practical Drug Therapy brings together for the first time in a single book really practical information on safe prescribing, with the background knowledge that underpins clinical pharmacology.Fully revised with new guidance and important safety information, this book is aimed primarily at medical students and trainees, it will also be invaluable to family doctors, clinical pharmacists, and nurse prescribers.

Contents
Introductory sections ; 1. Gastrointestinal system ; 2. Cardiovascular system ; 3. Respiratory system ; 4. Central nervous system ; 5. Infections ; 6. Endocrine system ; 7. Kidneys and the urinary tract ; 8. Malignant disease and immunosuppression ; 9. Nutrition and blood ; 10. Musculoskeletal and joints ; 11. Eye ; 12. Skin ; 13. Poisoning ; 14. Immunological products and vaccines ; 15. Relief of pain and anaesthetic drugs